# James H Mckerrow

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 103 papers | 6,253 citations | 76326 40 h-index | 74163 75 g-index |
| 112 all docs | 112 docs citations | 112 times ranked | 7300 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. Journal of Medicinal Chemistry, 2022, 65, 2956-2970. | 6.4 | 46 |
| 2 | Identification of Leucinostatins from Ophiocordyceps sp. as Antiparasitic Agents against Trypanosoma cruzi. ACS Omega, 2022, 7, 7675-7682. | 3.5 | 3 |
| 3 | Intramolecular Interactions Enhance the Potency of Gallinamide A Analogues against Trypanosoma cruzi. Journal of Medicinal Chemistry, 2022, 65, 4255-4269. | 6.4 | 9 |
| 4 | Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structureâ€“Activity Relationships, Antiviral Activity, and X-ray Structure Determination. Journal of Medicinal Chemistry, 2022, 65, 9376-9395. | 6.4 | 35 |
| 5 | Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L. Pharmaceuticals, 2022, 15, 744. | 3.8 | 5 |
| 6 | First report on prevalence of SARS-CoV-2 infection among health-care workers in Nicaragua. PLoS ONE, 2021, 16, e0246084. | 2.5 | 18 |
| 7 | A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells. ACS Chemical Biology, 2021, 16, 642-650. | 3.4 | 74 |
| 8 | Acanthamoeba Keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs. Expert Review of Anti-Infective Therapy, 2021, 19, 1427-1441. | 4.4 | 14 |
| 9 | Dysregulation of Glycerophosphocholines in the Cutaneous Lesion Caused by Leishmania major in Experimental Murine Models. Pathogens, 2021, 10, 593. | 2.8 | 7 |
| 10 | Computer-aided design of 1,4-naphthoquinone-based inhibitors targeting cruzain and rhodesain cysteine proteases. Bioorganic and Medicinal Chemistry, 2021, 41, 116213. | 3.0 | 31 |
| 11 | Structure-Based Optimization of Quinazolines as Cruzain and TbrCATL Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 13054-13071. | 6.4 | 19 |
| 12 | An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease. Pathogens, 2021, 10, 71. | 2.8 | 16 |
| 13 | Spatial metabolomics identifies localized chemical changes in heart tissue during chronic cardiac Chagas Disease. PLoS Neglected Tropical Diseases, 2021, 15, e0009819. | 3.0 | 18 |
| 14 | Macrofilaricidal Benzimidazoleâ€“Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 2. Ketone Linked Analogs. ACS Infectious Diseases, 2020, 6, 180-185. | 3.8 | 14 |
| 15 | Macrofilaricidal Benzimidazoleâ€“Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 1. Amide Linked Analogs. ACS Infectious Diseases, 2020, 6, 173-179. | 3.8 | 11 |
| 16 | Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole. PLoS Neglected Tropical Diseases, 2020, 14, e0008726. | 3.0 | 4 |
| 17 | The Antifungal Drug Isavuconazole Is both Amebicidal and Cysticidal against Acanthamoeba castellanii. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 23 |
| 18 | Molecular dissection of Chagas induced cardiomyopathy reveals central disease associated and druggable signaling pathways. PLoS Neglected Tropical Diseases, 2020, 14, e0007980. | 3.0 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity. Journal of Medicinal Chemistry, 2020, 63, 3298-3316. | 6.4 | 19 |
| 20 | Scaffold and Parasite Hopping: Discovery of New Protozoal Proliferation Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 249-257. | 2.8 | 17 |
| 21 | High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi. Microorganisms, 2020, 8, 472. | 3.6 | 10 |
| 22 | Identification of Four Amoebicidal Nontoxic Compounds by a Molecular Docking Screen of Naegleria fowleri Sterol Î”8â^Î”7-Isomerase and Phenotypic Assays. ACS Infectious Diseases, 2019, 5, 2029-2038. | 3.8 | 6 |
| 23 | Why Funding for Neglected Tropical Diseases Should Be a Global Priority. Clinical Infectious Diseases, 2018, 67, 323-326. | 5.8 | 21 |
| 24 | Identification of cysteine protease inhibitors as new drug leads against Naegleria fowleri. Experimental Parasitology, 2018, 188, 36-41. | 1.2 | 18 |
| 25 | Impact of Single Dose Praziquantel Treatment on Schistosoma haematobium Infection among School Children in an Endemic Nigerian Community. Korean Journal of Parasitology, 2018, 56, 577-581. | 1.3 | 6 |
| 26 | The diverse roles of cysteine proteases in parasites and their suitability as drug targets. PLoS Neglected Tropical Diseases, 2018, 12, e0005639. | 3.0 | 10 |
| 27 | Predictions of novel Schistosoma mansoni - human protein interactions consistent with experimental data. Scientific Reports, 2018, 8, 13092. | 3.3 | 9 |
| 28 | In Vitro Efficacy of Ebselen and BAY 11-7082 Against Naegleria fowleri. Frontiers in Microbiology, 2018, 9, 414. | 3.5 | 34 |
| 29 | Substrate Specificity of Cysteine Proteases Beyond the S2 Pocket: Mutagenesis and Molecular Dynamics Investigation of Fasciola hepatica Cathepsins L. Frontiers in Molecular Biosciences, 2018, 5, 40. | 3.5 | 10 |
| 30 | Update on drug development targeting parasite cysteine proteases. PLoS Neglected Tropical Diseases, 2018, 12, e0005850. | 3.0 | 31 |
| 31 | Two key cathepsins, TgCPB and TgCPL, are targeted by the vinyl sulfone inhibitor K11777 in in vitro and in vivo models of toxoplasmosis. PLoS ONE, 2018, 13, e0193982. | 2.5 | 14 |
| 32 | Cathepsin B expression in colorectal cancer in a Middle East population: Potential value as a tumor biomarker for late disease stages. Oncology Reports, 2017, 37, 3175-3180. | 2.6 | 23 |
| 33 | Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast. ACS Chemical Biology, 2017, 12, 422-434. | 3.4 | 26 |
| 34 | Mass Spectrometry-Based Chemical Cartography of a Cardiac Parasitic Infection. Analytical Chemistry, 2017, 89, 10414-10421. | 6.5 | 35 |
| 35 | The rule of five should not impede anti-parasitic drug development. International Journal for Parasitology: Drugs and Drug Resistance, 2017, 7, 248-249. | 3.4 | 36 |
| 36 | Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 104 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Editorial: Drug Development for Parasite-Induced Diarrheal Diseases. Frontiers in Microbiology, 2017, 8, 577. | 3.5 | 2 |
| 38 | 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection. PLoS Neglected Tropical Diseases, 2017, 11, e0006132. | 3.0 | 24 |
| 39 | CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM). PLoS Neglected Tropical Diseases, 2017, 11, e0006104. | 3.0 | 45 |
| 40 | Synthesis and Evaluation of Oxyguanidine Analogues of the Cysteine Protease Inhibitor WRR-483 against Cruzain. ACS Medicinal Chemistry Letters, 2016, 7, 77-82. | 2.8 | 26 |
| 41 | Polymorphisms of tumor necrosis factor alpha in Middle Eastern population with colorectal cancer. Tumor Biology, 2016, 37, 5529-5537. | 1.8 | 7 |
| 42 | X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action. Journal of Structural Biology, 2016, 194, 180-190. | 2.8 | 60 |
| 43 | Location, Location, Location: Five Facts about Tissue Tropism and Pathogenesis. PLoS Pathogens, 2016, 12, e1005519. | 4.7 | 31 |
| 44 | Heat shock protein 90 inhibitors repurposed against Entamoeba histolytica. Frontiers in Microbiology, 2015, 6, 368. | 3.5 | 13 |
| 45 | Prolyl Oligopeptidase from the Blood Fluke Schistosoma mansoni: From Functional Analysis to Anti-schistosomal Inhibitors. PLoS Neglected Tropical Diseases, 2015, 9, e0003827. | 3.0 | 34 |
| 46 | Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery. PLoS Neglected Tropical Diseases, 2015, 9, e0003878. | 3.0 | 74 |
| 47 | Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease. PLoS Pathogens, 2015, 11, e1005058. | 4.7 | 52 |
| 48 | Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs. Antimicrobial Agents and Chemotherapy, 2015, 59, 7923-7924. | 3.2 | 16 |
| 49 | Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Research, 2015, 116, 76-84. | 4.1 | 513 |
| 50 | Synthesis of a Sugar-Based Thiosemicarbazone Series and Structure-Activity Relationship versus the Parasite Cysteine Proteases Rhodesain, Cruzain, and Schistosoma mansoni Cathepsin B1. Antimicrobial Agents and Chemotherapy, 2015, 59, 2666-2677. | 3.2 | 57 |
| 51 | Targeting Ergosterol Biosynthesis in Leishmania donovani: Essentiality of Sterol 14alpha-demethylase. PLoS Neglected Tropical Diseases, 2015, 9, e0003588. | 3.0 | 90 |
| 52 | Repurposing Auranofin as a Lead Candidate for Treatment of Lymphatic Filariasis and Onchocerciasis. PLoS Neglected Tropical Diseases, 2015, 9, e0003534. | 3.0 | 88 |
| 53 | Recognition of the role of Natural Products as drugs to treat neglected tropical diseases by the 2015 Nobel prize in physiology or medicine. Natural Product Reports, 2015, 32, 1610-1611. | 10.3 | 19 |
| 54 | Genome-Directed Lead Discovery: Biosynthesis, Structure Elucidation, and Biological Evaluation of Two Families of Polyene Macrolactams against Trypanosoma brucei. ACS Chemical Biology, 2015, 10, 2373-2381. | 3.4 | 69 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Lead Identification to Clinical Candidate Selection: Drugs for Chagas Disease. Journal of Biomolecular Screening, 2015, 20, 101-111. | 2.6 | 27 |
| 56 | Trypsin- and Chymotrypsin-Like Serine Proteases in Schistosoma mansoni â€“ â€˜The Undiscovered Countryâ€™. PLoS Neglected Tropical Diseases, 2014, 8, e2766. | 3.0 | 31 |
| 57 | Activation Route of the Schistosoma mansoni Cathepsin B1 Drug Target: Structural Map with a Glycosaminoglycan Switch. Structure, 2014, 22, 1786-1798. | 3.3 | 34 |
| 58 | R-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi. ACS Medicinal Chemistry Letters, 2014, 5, 434-439. | 2.8 | 18 |
| 59 | 4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency. Journal of Medicinal Chemistry, 2014, 57, 6989-7005. | 6.4 | 43 |
| 60 | Determinants of disease phenotype in trypanosomatid parasites. Trends in Parasitology, 2014, 30, 342-349. | 3.3 | 58 |
| 61 | A Cysteine Protease Inhibitor Rescues Mice from a Lethal Cryptosporidium parvum Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 6063-6073. | 3.2 | 52 |
| 62 | Rational Development of 4-Aminopyridyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51 as Anti-Chagas Agents. Journal of Medicinal Chemistry, 2013, 56, 7651-7668. | 6.4 | 43 |
| 63 | Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51. PLoS Neglected Tropical Diseases, 2012, 6, e1736. | 3.0 | 54 |
| 64 | Cruzain. Advances in Experimental Medicine and Biology, 2011, 712, 100-115. | 1.6 | 85 |
| 65 | Structural Basis for Inhibition of Cathepsin B Drug Target from the Human Blood Fluke, Schistosoma mansoni. Journal of Biological Chemistry, 2011, 286, 35770-35781. | 3.4 | 60 |
| 66 | The Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion. PLoS Pathogens, 2011, 7, e1002139. | 4.7 | 98 |
| 67 | In Vitro and In Vivo Studies of the Trypanocidal Properties of WRR-483 against Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2010, 4, e825. | 3.0 | 66 |
| 68 | Identification and Optimization of Inhibitors of Trypanosomal Cysteine Proteases: Cruzain, Rhodesain, and TbCatB. Journal of Medicinal Chemistry, 2010, 53, 52-60. | 6.4 | 103 |
| 69 | A Nonazole CYP51 Inhibitor Cures Chagasâ€™ Disease in a Mouse Model of Acute Infection. Antimicrobial Agents and Chemotherapy, 2010, 54, 2480-2488. | 3.2 | 56 |
| 70 | Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 4891-4905. | 6.4 | 199 |
| 71 | Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit. PLoS Neglected Tropical Diseases, 2009, 3, e372. | 3.0 | 60 |
| 72 | Vinyl Sulfones as Antiparasitic Agents and a Structural Basis for Drug Design. Journal of Biological Chemistry, 2009, 284, 25697-25703. | 3.4 | 234 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6218-6221. | 2.2 | 56 |
| 74 | Divergent Modes of Enzyme Inhibition in a Homologous Structureâ"Activity Series. Journal of Medicinal Chemistry, 2009, 52, 5005-5008. | 6.4 | 84 |
| 75 | Development of protease inhibitors for protozoan infections. Current Opinion in Infectious Diseases, 2008, 21, 668-672. | 3.1 | 108 |
| 76 | RNA Interference of Trypanosoma brucei Cathepsin B and L Affects Disease Progression in a Mouse Model. PLoS Neglected Tropical Diseases, 2008, 2, e298. | 3.0 | 76 |
| 77 | A Cysteine Protease Inhibitor Cures Chagas' Disease in an Immunodeficient-Mouse Model of Infection. Antimicrobial Agents and Chemotherapy, 2007, 51, 3932-3939. | 3.2 | 163 |
| 78 | Schistosomiasis Mansoni: Novel Chemotherapy Using a Cysteine Protease Inhibitor. PLoS Medicine, 2007, 4, e14. | 8.4 | 229 |
| 79 | Chemical Composition and Cruzain Inhibitory Activity of Croton draco Bark Essential Oil from Monteverde, Costa Rica. Natural Product Communications, 2007, 2, 1934578X0700200. | 0.5 | 4 |
| 80 | Cruzain Inhibitory Activity of Leaf Essential Oils of Neotropical Lauraceae and Essential Oil Components. Natural Product Communications, 2007, 2, 1934578X0700201. | 0.5 | 18 |
| 81 | 3-O-(3â€²-Hydroxytetradecanoyl)lupeol from Sorocea trophoides Inhibits Cruzain. Natural Product Communications, 2007, 2, 1934578X0700200. | 0.5 | 6 |
| 82 | Inhibition of Cruzain by Triterpenoids Isolated from a Salacia Species from Monteverde, Costa Rica. Natural Product Communications, 2007, 2, 1934578X0700201. | 0.5 | 5 |
| 83 | PROTEASES IN PARASITIC DISEASES. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 497-536. | 22.4 | 341 |
| 84 | Reversible inhibition of cathepsin L-like proteases by 4-mer pseudopeptides. FEBS Letters, 2001, 507, 362-366. | 2.8 | 8 |
| 85 | Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2759-2762. | 2.2 | 82 |
| 86 | Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense. Molecular and Biochemical Parasitology, 2001, 118, 61-73. | 1.1 | 155 |
| 87 | Aryl ureas represent a new class of anti-trypanosomal agents. Chemistry and Biology, 2000, 7, 733-742. | 6.0 | 77 |
| 88 | A target within the target: probing cruzainâ€™s P1â€² site to define structural determinants for the Chagasâ€™ disease protease. Structure, 2000, 8, 831-840. | 3.3 | 100 |
| 89 | The high stability of cruzipain against pH-induced inactivation is not dependent on its C-terminal domain. FEBS Letters, 2000, 469, 29-32. | 2.8 | 7 |
| 90 | Identification of a cDNA encoding an active asparaginyl endopeptidase ofSchistosoma mansoniand its expression inPichia pastoris1. FEBS Letters, 2000, 466, 244-248. | 2.8 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. International Journal for Parasitology, 1999, 29, 833-837. | 3.1 | 129 |
| 92 | A Phenylalanine Hydroxylase Gene from the Nematode C. Elegans is Expressed in the Hypodermis. Journal of Neurogenetics, 1999, 13, 157-180. | 1.4 | 22 |
| 93 | Expression and alteration of the S2 subsite of the Leishmania major cathepsin B-like cysteine protease. Biochemical Journal, 1999, 340, 113-117. | 3.7 | 35 |
| 94 | Design and synthesis of dipeptidyl Î±â€²,Î²â€²-epoxy ketones, potent irreversible inhibitors of the cysteine protease cruzain. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2809-2812. | 2.2 | 47 |
| 95 | Substrate inhibition of cruzipain is not affected by the C-terminal domain. FEBS Letters, 1998, 429, 129-133. | 2.8 | 20 |
| 96 | Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection. Journal of Experimental Medicine, 1998, 188, 725-734. | 8.5 | 375 |
| 97 | Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Molecular and Biochemical Parasitology, 1993, 58, 17-24. | 1.1 | 155 |
| 98 | Tumour necrosis factor Î± restores granulomas and induces parasite egg-laying in schistosome-infected SCID mice. Nature, 1992, 356, 604-607. | 27.8 | 442 |
| 99 | Recent Insights into the Structure and Function of a Larval Proteinase Involved in Host Infection by a Multicellular Parasite. Experimental Biology and Medicine, 1991, 197, 119-124. | 2.4 | 17 |
| 100 | Tissue identification and histologic study of six lung specimens from Egyptian mummies. American Journal of Physical Anthropology, 1987, 72, 43-48. | 2.1 | 33 |
| 101 | Enzyme Histochemical Comparison of Biomphalaria glabrata Amebocytes With Human Granuloma Macrophages. Journal of Leukocyte Biology, 1985, 37, 341-347. | 3.3 | 16 |
| 102 | Hormone receptors in hepatoblastoma: A demonstration of both estrogen and progesterone receptors. Cancer, 1982, 50, 1828-1832. | 4.1 | 14 |
| 103 | Murine embryonal carcinoma hybrids: Decreased ability to spontaneously differentiate as a dominant trait. Journal of Cellular Physiology, 1981, 109, 195-204. | 4.1 | 12 |